Ask AI
CDK4/6 Inhibitors HR Positive HER2 Negative EBC

CE

Case Challenge: Optimizing Patient–Provider Communication About CDK4/6 Inhibitors for Treatment of HR+/HER2- EBC

Physician Assistants: maximum of 1.00 hour of AAPA Category 1 CME credit

Registered Nurses: 1.00 Nursing contact hour

Released: May 22, 2026

Expiration: November 21, 2026

Activity

Progress
1 2
Course Completed

  1. (note: the recent update to version 3.2026 did not affect the content of this activity): Gradishar WJ, Moran MS, Abraham J, et al. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 3.2026. Accessed May 8, 2026. To view the most recent version, visit NCCN.org.
  2. Ribociclib [prescribing information]. East Hanover NJ: Novartis Pharmaceuticals Corporation; 2025.
  3. Abemaciclib [prescribing information]. Indianapolis, IN: Lilly USA, LLC; 2025.
  4. Johnston S, Martin M, O’Shaughnessy J, et al. Overall survival with abemaciclib in early breast cancer. Ann Oncology. 2025;37:155-165.
  5. Crown J, Stroyakovskii D, Yardley DA, et al. Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival. ESMO Open. 2025;10:105858.
  6. Rastogi P, O'Shaughnessy J, Martin M, et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. J Clin Oncol. 2024;42:987-993.
  7. Fasching PA, Slamon D, Nowecki Z, et al. Health-related quality of life in patients with HR+/HER2- early breast cancer treated with ribociclib plus a nonsteroidal aromatase inhibitor: Results from the NATALEE trial. Clin Cancer Res. 2025;31:1625
  8. Tolaney SM, Guarneri V, Seo JH, et al. Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer. Eur J Cancer. 2024;199:113555.
  9. Slamon D, Lipatov O, Nowecki Z, et al. Ribociclib plus Endocrine Therapy in Early Breast Cancer. N Engl J Med. 2024;390:1080-1091.
  10. Johnston SRD, Toi M, O'Shaughnessy J, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24:77-90.
  11. Rugo HS, Huober J, García-Sáenz JA, et al. Management of abemaciclib-associated adverse events in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3. Oncologist. 2021;26:e53-e65.
  12. Gyori D, Orr J. Positive quality intervention: management of abemaciclib (Verzenio) associated diarrhea. ncoda.org/wp-content/uploads/2025/03/Management-of-Abemaciclib-Verzenio-Associated-Diarrhea_PQI_NCODA.pdf. Accessed May 7, 2026.
  13. Goetz MP, Johnston SRD, Martin M, et al. Impact of dose reductions on adjuvant abemaciclib efficacy: analyses from the monarchE study. NPJ Breast Cancer. 2024;10:31.
  14. Hamilton E, Decker T, Rugo HS, et al. Impact of ribociclib dose reduction on efficacy in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer in NATALEE. Presented at: 42nd Annual Miami Breast Cancer Conference. March 6-9, 2025; Poster 20.
  15. Food and Drug Administration. Patient-friendly language for cancer clinical trials. https://www.fda.gov/about-fda/oncology-center-excellence/patient-friendly-language-cancer-clinical-trials. Accessed May 7, 2026.
  16. De Laurentiis M, Buonaiuto R, Buono G, et al. In defense of adjuvant CDK4/6 inhibitors in early breast cancer. JCO. 2025;43:3691.
  17. Hortobagyi GN, Lacko A, Cruz F, et al. A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial. Ann Oncology. 2025;36:149-157.
  18. Chappell JC, Turner PK, Pak YA, et al. Abemaciclib inhibits renal tubular secretion without changing glomerular filtration rate. Clin Pharmacol Ther. 2018; 105:1187-1195.